New hope for lymphoma patients: mosunetuzumab under review
NCT ID NCT07278921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of 25 adults with follicular lymphoma that returned or didn't respond to at least two prior treatments. All patients received mosunetuzumab through a compassionate use program. Researchers want to see how well the drug works and what side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mosunetuzumab
- What this could lead to
- If successful, this could provide a treatment option for patients with follicular lymphoma who have not responded to other therapies.
- What could go wrong
- This is a small, retrospective observational study, not a controlled trial. Results may not apply to all patients, and there are risks like infusion reactions and nervous system side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS Ospedale San Raffaele
RECRUITINGMilan, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New cocktail of four drugs hopes to tackle tough lymphoma
- New hope for lymphoma patients: experimental drug combo enters final trial phase
- New immune cell combo tackles tough lymphoma
- Off-the-Shelf CAR t cells take on tough lymphomas
- New hope for lymphoma patients: zanubrutinib combo enters phase 3 trial
- New hope for hard-to-treat lymphoma: targeted drug combo tested in large trial